



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
June 1, 2026

Notice Regarding the Joint Establishment of a Working Group Focused on the Clinical Diagnostic Reagents Wholesaling Business by Alfresa Corporation and Seiko CO., LTD

Subsidiary Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”) has decided to establish a working group focused on enhancing and improving the efficiency of supply chains in the clinical diagnostic reagents wholesaling business jointly with Seiko CO., LTD (head office: Fukuoka City, Fukuoka Prefecture; president: Masatoshi In; hereinafter “Seiko”). The details are as follows.

1. Background and Purpose of the Decision

In the domestic medical diagnostic reagents industry, demand for testing is expanding amid the aging of Japan’s population and an increase in patients with chronic diseases. Furthermore, the enhancement and diversification of testing is being driven by advancements in personalized medicine, including the proliferation of genomic testing such as cancer genomic profiling^{*1} and companion diagnostics.^{*2} Accompanying the aforementioned increase in demand for testing are rising raw material and logistics costs, which further raise the importance of stable supplies of medical diagnostic reagents. Therefore, enhancing and heightening the efficiency of supply chains has become a priority undertaking throughout the domestic medical diagnostic reagents industry.

The Alfresa Group has positioned medical products^{*3} as a growth area in its Medium- to Long-Term Vision,^{*4} which serves as a growth strategy through to fiscal 2032. Furthermore, under 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength,^{*5} we have adopted as a business strategy for the Ethical Pharmaceuticals Wholesaling Business the strengthening of our nationwide network for ethical pharmaceuticals and medical products. In addition to ethical pharmaceuticals, Alfresa sources diagnostic reagents, medical equipment and materials, nutritional foods, and other products from around 1,000 manufacturers in Japan and overseas. We have established a nationwide distribution network

of approximately 170 locations through which we deliver such products safely, securely, and in high quality to hospitals, clinics, and pharmacies.

Meanwhile, as a trading company specializing in medical diagnostic reagents, Seiko has cultivated long-standing business relationships with medical institutions since its founding in 1950, with a focus on institutions throughout the Kyushu region and in Okinawa Prefecture. Seiko addresses the diverse needs of the front lines of healthcare by providing a stable supply of reagents, medical devices, and other products as well as comprehensive services that combine system development, operational support, maintenance, and more.

Alfresa, with its nationwide distribution network, and Seiko, which offers highly specialized services in the medical diagnostic reagents industry, have decided to establish a working group in which they will leverage their respective expertise in order to respond to changes in the medical diagnostic reagents industry. Moving forward, the two companies will explore solutions to industry-wide issues, including how to enhance and improve the efficiency of distribution and logistics for medical diagnostic reagents and ensure their stable supply.

*1 Testing that comprehensively analyzes genetic abnormalities in cancer cells

*2 Tests performed to determine whether a particular therapeutic drug will be effective for a patient prior to its administration, thereby contributing to the realization of personalized medicine, in which treatment is tailored to each patient's individual condition

*3 Diagnostic reagents, medical devices and materials, nutritional foods, etc.

*4 Reference: Notice Regarding the Formulation of the Alfresa Group's Medium- to Long-Term Vision (published on May 15, 2023, on the Alfresa Holdings Corporation corporate website)

https://www.alfresa.com/eng/ir/pdf/mediumtolong_termvision.pdf

*5 Reference: Notice Regarding the Formulation of the 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength (published on May 15, 2025, on the Alfresa Holdings Corporation corporate website)

<https://www.alfresa.com/eng/ir/pdf/management-plan.pdf>

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>